UnitedHealthcare Medicare Advantage reimbursement policy — in vitro chemotherapy sensitivity and resistance assays
Defines UnitedHealthcare Medicare Advantage reimbursement methodology for in vitro chemotherapy sensitivity and resistance assays billed on CMS 1500 or UB04 forms and who it affects (Medicare Advantage network providers).
New Policy.
Policy published 6/1/2026.
Coverage Criteria
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.